Anti-CCP antibody in rheumatoid arthritis patients and its relation with severity of the disease

Abstract

Background: Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by chronic and erosive polyarthritis causing irreversible joint disability. It is the most common persistent inflammatory arthritis, affecting from 0.5 to 1% of the general population worldwide. Antibodies to citrullinated proteins (anti-CCP antibody) have been described in patients with RA and these appear to be the most specific marker of the disease. Methods: This cross-sectional study was carried out at department of medicine, Sher-E-Bangla Medical College Hospital, Barisal Form July’ 2016 to December’ 2016. All rheumatoid arthritis patients attending at OPD and those got admitted under Medicine Dept, who was satisfying the inclusion and exclusion criteria were included consecutively and purposively in this study. Results: Total 70 cases were included; the mean age was found 46.57±13.10 years in anti-CCP antibody positive group and 44.19±11.21 years in anti-CCP antibody negative group. Female were predominant in both groups. Duration of disease was around 8 years in both groups. Mean ESR was 29.0±22.0 mm in anti-CCP antibody positive group and 12.25±10.6 mm in anti-CCP antibody negative group. Mean rheumatoid factor was 189.4±102.1 U/L in anti-CCP antibody positive group and 66.5±36.0 U/L in anti-CCP antibody negative group. Mean DAS 28 score was 4.6±1.4 and 3.6±1.3 in anti-CCP antibody positive and negative group respectively. The mean difference was statistically significant (p<0.05) between the groups. Patients in disease remission had lower anti-CCP antibody titer than those with low, moderate or high disease activity. Significantly positive correlation (r=0.596; p=0.001) between severity of rheumatoid arthritis and anti CCP antibody level was observed. Conclusion: In RA patients’ disease was more severe in anti-CCP antibody positive group and significantly positive correlation between anti-CCP antibody level with disease severity of RA was observed. BIRDEM Med J 2022; 12(1): 36-40

Assessment of Wnt-5a, Anti-SMA, FGF-23, and Anti-CCP Biomarkers in Patients with Rheumatoid Arthritis

“…Moreover, anti-CCP expression was also reported to be significantly higher in RA patients, similar to other studies [26,47,48]. Generally, anti-CCP is expressed in RA patients [49] because CCP is absent from joints in normal conditions. Nevertheless, various CCPs are present during different forms of inflammation, including RA.…”

The Prevalence of Eye Involvements in Rheumatoid Arthritis and Their Correlation With Anti-Cyclic Citrullinated Peptide Antibody in Sulaimani Governorate/Iraq

“…Additionally, in healthy persons and patients with undifferentiated arthritis, the presence of anti-CCP antibodies appears to be a highly reliable predictor of the future establishment of RA (36) . Anti-CCP antibodies can be identified in asymptomatic individuals years before the manifestation of RA, and they are connected to a more severe disease advancement (10) . This study detected the anti-CCP antibody in 75 out of 121 RA patients, equivalent to a 62% prevalence rate.…”

“…Anti-CCP antibodies recognise peptides in which arginine has been converted to citrulline by peptidyl arginine deaminase, found in inflammatory synovium and mucosal tissues (9) . Anti-CCP is closely linked with a more severe course of the disorder and can be detected in asymptomatic patients years before the development of RA (9)(10)(11) . Since 2010, Anti-CCP has been added as a criterion in the ACR/ EULAR guidelines for the classification of RA (12,13) .…”